NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?

Novo Nordisk shares plummeted 21.8% after the company drastically cut its 2025 sales and operating profit growth outlooks, now projecting sales to grow 8-14% (down from 13-21%) and operating profit 10-16% (down from 16-24%). This significant revision is primarily due to weaker-than-expected momentum for its key semaglutide drugs, Wegovy and Ozempic, citing persistent challenges in the U.S. obesity market from compounded GLP-1s, slower market expansion, and intensifying competition from rivals like Eli Lilly.

Analysis

Novo Nordisk (NVO) shares experienced a severe correction, plunging 21.8%, following a significant downward revision of its 2025 financial outlook. The company slashed its sales growth forecast to 8-14% from 13-21% and its operating profit growth projection to 10-16% from 16-24%. This guidance cut is attributed to multifaceted headwinds for its flagship semaglutide products, Wegovy and Ozempic. Key drivers include weaker-than-expected momentum in the U.S. obesity market, where the persistent use of illegal, compounded GLP-1 drugs is directly undermining Wegovy's uptake despite ongoing litigation. Furthermore, Wegovy's market penetration has lagged expectations due to slower overall market expansion and intensifying competition, a trend also impacting Ozempic in the diabetes segment. The revised operating profit guidance incorporates this weaker sales outlook and a negative mid-single-digit impact from the acquisition of three Catalent manufacturing facilities. This pessimistic outlook is further substantiated by a preliminary Q2 earnings miss, with EPS of 91 cents falling short of the 94-cent consensus estimate. In stark contrast, competitor Eli Lilly (LLY) demonstrates formidable strength, with its tirzepatide drugs Mounjaro and Zepbound generating $6.15 billion in Q1 2025, constituting nearly half of its total revenue and highlighting a significant competitive threat to Novo Nordisk's market dominance.

Key Decisions for Investors

• Investors should re-evaluate Novo Nordisk's long-term growth assumptions and valuation multiples, as the revised guidance signals a fundamental deceleration and persistent market access challenges.
• The starkly contrasting performance and outlook between Novo Nordisk and Eli Lilly suggest a potential pairs trade opportunity, favoring a long position in LLY against a short position in NVO to capture the ongoing market share shift in the obesity drug space.
• Closely monitor Novo Nordisk's upcoming detailed earnings call on August 6 for management's commentary on the effectiveness of its legal actions against compounded drugs and any new strategies to regain market momentum.
• The negative mid-single-digit impact on operating profit from the Catalent facility acquisition should be factored into profitability models, as it represents a tangible drag on near-term earnings potential.